Dong-E-E-Jiao (SHE:000423) expects an attributable profit of between 1.5 billion yuan and 1.6 billion yuan for the year 2024, up from 1.15 billion yuan a year prior, a Friday bourse filing by parent China Resources Pharmaceutical Group (HKG:3320) said.
The pharmaceutical company's higher anticipated profit was mainly due to a steady growth in operating performance.